Cristina Molina-Hidalgo

Dr. Cristina Molina-Hidalgo

Department of Physical Education and Sports, PROFITH ‘PROmoting FITness and Health through physical activity’ research group, School of Sport Sciences, University of Granada, Granada 18071, Spain
orcid
Postdoctoral Research Scientist

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2020 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
LJLucas Jurado-Fasoli
Lucas Jurado-Fasoli
ADAlejandro De-la-O
Alejandro De-la-O
Cristina Molina-HidalgoCristina Molina-Hidalgo
Cristina Molina-Hidalgo
JMJairo H. Migueles
Jairo H. Migueles
MCManuel J. Castillo
Manuel J. Castillo
FAFrancisco J. Amaro‐Gahete
Francisco J. Amaro‐Gahete

7 August 2023 in Journal of Sport and Health Science
Verified
Journal Article
Open access
MRMaría Rodriguez-Ayllon
María Rodriguez-Ayllon
PSPatricio Solis-Urra
Patricio Solis-Urra
CACristina Arroyo-Ávila
Cristina Arroyo-Ávila
MÁMiriam Álvarez-Ortega
Miriam Álvarez-Ortega
PMPablo Molina-García
Pablo Molina-García
IEIrene Esteban-Cornejo
Irene Esteban-Cornejo
One of the pathological hallmarks distinguishing Alzheimer's disease from other dementias is the accumulation of amyloid beta (Aβ). Higher physical activity is associated with decreased dementia risk, and one potential path could be through Aβ levels modulation. We aimed to explore the relationship between physical activity and Aβ in middle-aged and older adults. A systematic search of PubMed, Web of Science, PsycINFO, Cochrane Central Register of Controlled Trials, and SPORTDiscus was performed from inception to April 28, 2022. Studies were eligible if they included physical activity and Aβ data in adults aged 45 years or older. Multi-level meta-analyses of intervention and observational studies were performed to examine the role of physical activity in modulating Aβ levels. In total, 37 articles were included (8 randomized controlled trials, 3 non-randomized controlled trials, 4 prospective longitudinal studies, and 22 cross-sectional studies). The overall effect size of physical activity interventions on changes in blood Aβ was medium (pooled standardized mean difference = -0.69, 95% confidence interval (95%CI): -1.41 to 0.03; I2 = 74.6%). However, these results were not statistically significant, and there were not enough studies to explore the effects of physical activity on cerebrospinal fluid (CSF) and brain Aβ. Data from observational studies were examined based on measurements of Aβ in the brain using positron emission tomography scans, CSF, and blood. Higher physical activity was positively associated with Aβ only in the CSF (Estimate r = 0.12; 95%CI: 0.05-0.18; I2 = 38.00%). Physical activity might moderately reduce blood Aβ in middle-aged and older adults. However, results were only near statistical significance and might be interpreted with caution given the methodological limitations observed in some of the included studies. In observational studies, higher levels of physical activity were positively associated with Aβ only in CSF. Therefore, further research is needed to understand the modulating role of physical activity in the brain, CSF, and blood Aβ, as well as its implication for cognitive health.

11 October 2023 in Frontiers in Physiology
Verified
Journal Article
Open access
Cristina Molina-HidalgoCristina Molina-Hidalgo
Cristina Molina-Hidalgo
CSChelsea M. Stillman
Chelsea M. Stillman
ACAudrey M. Collins
Audrey M. Collins
Daniel Velázquez-DíazDaniel Velázquez-Díaz
Daniel Velázquez-Díaz
HRHayley S. Ripperger
Hayley S. Ripperger
KEKirk I. Erickson
Kirk I. Erickson
Physical activity (PA) in the form of aerobic exercise (AE) preserves and improves neurocognitive function across the lifespan. However, a mechanistic understanding of the pathways by which aerobic exercise impacts brain health is still lacking, particularly with respect to stress-related pathways. One mechanistic hypothesis is that AE improves neurocognitive health in part by modifying circulating levels of stress-related hormones and signaling factors associated with the hypothalamic-pituitary-adrenal (HPA) axis and autonomic nervous system (ANS), as commonly measured by the biomarkers cortisol (CORT) and salivary α-amylase (sAA). Thus, this hypothesis predicts that changes in stress biomarkers, such as CORT and sAA, are possible explanatory pathways mediating the positive effects of AE on neurocognitive health. In the present review article, we provide a summary of available studies examining the possibility that exercise-induced changes to stress biomarkers could partly account for exercise-related improvements in neurocognitive health. Our review indicates that despite the intuitive appeal of this hypothesis, there is insufficient evidence available to conclude that chronic and habitual AE affects neurocognitive health by altering stress biomarker pathways. The cross-sectional nature of the majority of reviewed studies highlights the need for well-controlled studies to adequately test this hypothesis.

19 October 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ECElena Calandre
Elena Calandre
JTJavier Hidalgo Tallón
Javier Hidalgo Tallón
RMRocio Molina-Barea
Rocio Molina-Barea
FRFernando Rico-Villademoros
Fernando Rico-Villademoros
Cristina Molina-HidalgoCristina Molina-Hidalgo
Cristina Molina-Hidalgo
MSMahmoud Slim
Mahmoud Slim
Gastrointestinal symptomatology is frequent among patients with fibromyalgia, which increases disease burden and lacks specific treatment, either pharmacological or non-pharmacological. We aimed to evaluate the efficacy and tolerability of a multi-strain probiotic, VSL#3®, for the treatment of fibromyalgia-associated gastrointestinal manifestations. This randomized, placebo-controlled trial included 12 weeks of probiotic or placebo treatment followed by 12 weeks of follow up. The primary outcome variable was the mean change from the baseline to the endpoint in the composite severity score of the three main gastrointestinal symptoms reported by patients with fibromyalgia (abdominal pain, abdominal bloating and meteorism). Secondary outcome variables were the severity of additional gastrointestinal symptoms, fibromyalgia severity, depression, sleep disturbance, health-related quality of life and patients’ overall impression of improvement. No differences were found between VSL#3® (n = 54) and the placebo (n = 56) in the primary outcome (estimated treatment difference: 1.1; 95% confidence interval [CI]: −2.1, 4.2; p = 0.501), or in any of the secondary outcomes. However, responders to VSL#3 were more likely to maintain any improvement during the follow-up period compared to responders in the placebo arm. Overall, VSL#3 tolerability was good. Our data could not demonstrate any beneficial effects of VSL#3® either on the composite score of severity of abdominal pain, bloating and meteorism or in any of the secondary outcome variables. More research is needed to elucidate specific factors that may predict a favourable response to treatment in patients with fibromyalgia.

4 February 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMiguel Seral-Cortes
Miguel Seral-Cortes
SSSergio Sabroso-Lasa
Sergio Sabroso-Lasa
Pilar Miguel-EtayoPilar Miguel-Etayo
Pilar Miguel-Etayo
Marcela Gonzalez-GrossMarcela Gonzalez-Gross
Marcela Gonzalez-Gross
EGEva Gesteiro
Eva Gesteiro
ILIdoia Labayen
Idoia Labayen
Obesity is the result of interactions between genes and environmental factors. Since monogenic etiology is only known in some obesity-related genes, a genetic risk score (GRS) could be useful to determine the genetic predisposition to obesity. Therefore, the aim of our study was to build a GRS able to predict genetic predisposition to overweight and obesity in European adolescents. A total of 1069 adolescents (51.3% female), aged 11–19 years participating in the Healthy Lifestyle in Europe by Nutrition in Adolescence (HELENA) cross-sectional study were genotyped. The sample was divided in non-overweight (non-OW) and overweight/obesity (OW/OB). From 611 single nucleotide polymorphisms (SNP) available, a first screening of 104 SNPs univariately associated with obesity (p < 0.20) was established selecting 21 significant SNPs (p < 0.05) in the multivariate model. Unweighted GRS (uGRS) was calculated by summing the number of risk alleles and weighted GRS (wGRS) by multiplying the risk alleles to each estimated coefficient. The area under curve (AUC) was calculated in uGRS (0.723) and wGRS (0.734) using tenfold internal cross-validation. Both uGRS and wGRS were significantly associated with body mass index (BMI) (p < .001). Both GRSs could potentially be considered as useful genetic tools to evaluate individual’s predisposition to overweight/obesity in European adolescents.

16 December 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
MSMiguel Seral-Cortes
Miguel Seral-Cortes
SSSergio Sabroso-Lasa
Sergio Sabroso-Lasa
Pilar Miguel-EtayoPilar Miguel-Etayo
Pilar Miguel-Etayo
Marcela Gonzalez-GrossMarcela Gonzalez-Gross
Marcela Gonzalez-Gross
EGEVA GESTEIRO
EVA GESTEIRO
Idoia LabayenIdoia Labayen
Idoia Labayen
Obesity and metabolic syndrome (MetS) are worldwide major health challenges. The Mediterranean diet (MD) is associated with a better cardiometabolic profile, but these beneficial effects may be influenced by genetic variations, modulating the predisposition to obesity or MetS. The aim was to assess whether interaction effects occur between an obesity genetic risk score (obesity-GRS) and the MD on adiposity and MetS in European adolescents. Multiple linear regression models were used to assess the interaction effects of an obesity-GRS and the MD on adiposity and MetS and its components. Interaction effects between the MD on adiposity and MetS were observed in both sex groups (p < 0.05). However, those interaction effects were only expressed in a certain number of adolescents, when a limited number of risk alleles were present. Regarding adiposity, a total of 51.1% males and 98.7% females had lower body mass index (BMI) as a result of higher MD adherence. Concerning MetS, only 9.9% of males with higher MD adherence had lower MetS scores. However, the same effect was observed in 95.2% of females. In conclusion, obesity-related genotypes could modulate the relationship between MD adherence and adiposity and MetS in European adolescents; the interaction effect was higher in females than in males.